A Phase 4 interventional study of Anti-Tlymphocyte Globulins and Anti-Thymocyte Globulins in CKD (Chronic Kidney Disease) Stage 5T, Diabetes Mellitus and Simultaneous Pancreas Kidney Transplantation, sponsored by Tianjin First Central Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-03-20.
Sponsored by Tianjin First Central Hospital · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 245 studies in Renal Insufficiency, Chronic with a site in China — 94 open to participants now, 107 under way, 17 of them phase 3. Renal Insufficiency, Chronic · China.
Among the 245 studies in Renal Insufficiency, Chronic with a site in China, this one is the 131st largest by planned enrollment of the 164 interventional ones that give a count, is one of 13 that started in 2018, is one of 38 in phase 4, and was the 67th registered.
3,095 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →94 of the 245 studies in Renal Insufficiency, Chronic with a site in China are open now. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in China
Ages 18+
Atom Therapeutics Co., Ltd · Sites in China, Australia
Ages 18–75
AstraZeneca · Sites in China, United States, Argentina and 24 more countries
Ages 18–99
AstraZeneca · Sites in China, United States, Argentina and 34 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in China, United States, Colombia and 5 more countries
Ages 2–18
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 435 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
245 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 24 · Phase 3 39 · Phase 4 38
First in 2000; this study’s year is marked. 13 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is below the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 182 across the 164 interventional studies, 1,350 across the 80 observational. Of the 84 that completed or were terminated, 21 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 245 have an industry lead sponsor. The 10 most frequent:
Tianjin First Central Hospital is the lead sponsor of 18 studies on the registry; 10 are open to participants now.
Tianjin First Central Hospital has 1 study filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
22 of the studies in Renal Insufficiency, Chronic with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07122401Phase 3Shaanxi Micot Pharmaceutical Technology Co., Ltd.Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism | 2026-11-26 |
| NCT06531824Phase 3Boehringer IngelheimEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | 2026-12-31 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT05349955Shanghai Zhongshan HospitalEffects and Safety of Diabetic GUideline Algorithm Implementation Performed by Primary Care Physicians in the Community | 2026-11-30 |
| NCT07262333Beijing Continent Pharmaceutical Co, Ltd.A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency | 2026-12-01 |
Add all 22 to your calendar (.ics) → With an account.
Among the 245 studies in Renal Insufficiency, Chronic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A single-centre, prospective, observational study to evaluate the safety and efficacy of Polyclonal Antibodies in simultaneous Pancreas Kidney Transplant recipients.
Polyclonal antibody mainly contains Antit-Tlymphocyte globulins(Grafalon) and Anti-thymocyte globulins(ATG). To investigate the efficacy and safety of polyclonal antibodies induction regimen using Grafalon compared with ATG in de novo simultaneous pancreas kidney transplant recipients. The primary analysis of this study is to demonstrate the non-inferiority of the two regimens with regard to efficacy, defined as failure rate.
The secondary objective of the study is the assessment of safety and further efficacy parameters in terms of incidence of acute rejections, graft/patient survival, DGF(delayed graft function), pancreas function and renal function
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
intravenous，2mg/kg/d，for 5 days
Drug: Anti-Tlymphocyte Globulins
intravenous，1.5mg/kg/d，for 4 days
Drug: Anti-Thymocyte Globulins
Drug pages: Anti-human t-lymphocyte immunoglobulin from rabbits · Thymoglobulin
Induction therapy regimen in simultaneous pancreas kidney transplantation
Also known as: Grafalon, ATG-F
Induction therapy regimen in simultaneous pancreas kidney transplantation
Also known as: ATG
Incidence and severity of adverse event
Incidence of patient's death,graft loss,acute rejection
Time frame: up to 3 months post-transplantation
Plan to share: No
Started Mar 2018 (actual). Primary completion is estimated for Mar 2021, 36 months after the start.
Of 100 non-industry phase 4 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 67. This study's planned 36 months is below that.
Counting every sponsor, half of 116 studies reached it within 43 months; a quarter within 22 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Anti-human t-lymphocyte immunoglobulin from rabbits · Thymoglobulin
Renal Insufficiency, Chronic →
Tianjin First Central Hospital